NUCB2/nesfatin and its proteolytically cleaved product nesfatin-1 are recently discovered anorexigenic hypothalamic neuroproteins involved in energy homeostasis. It is expressed both centrally and in peripheral tissues, and appears to have potent metabolic actions. NUCB2/nesfatin neurons are activated in response to stress. Central nesfatin-1 administration elevates circulating ACTH and corticosterone levels. Bilateral adrenalectomy increased NUCB2/nesfatin mRNA levels in rat paraventricular nuclei. To date, studies have not assessed the effects of nesfatin-1 stimulation on human adrenocortical cells. Therefore, we investigated the expression and effects of nesfatin-1 in a human adrenocortical cell model (H295R). Our findings demonstrate that NUCB2 and nesfatin-1 are expressed in human adrenal gland and human adrenocortical cells (H295R). Stimulation with nesfatin-1 inhibits the growth of H295R cells and promotes apoptosis, potentially via the involvement of Bax, BCL-XL and BCL-2 genes as well as ERK 1/2 , p38 and JNK1/2 signalling cascades. This has implications for understanding the role of NUCB2/nesfatin in adrenal zonal development. NUCB2/nesfatin may also be a therapeutic target for adrenal cancer. However, further studies using in vivo models are needed to clarify these concepts.
Introduction
Optimal development of adrenal tissue requires a balance between cell proliferation and apoptosis (programmed cell death); apoptosis removes harmful, damaged or unwanted cells. Within the adrenal gland, constant dynamic changes control the rate of cell growth as a result of alterations in physiological and pathophysiological conditions (Keegan & Hammer 2002 , Kirschner 2002 . Regulation of adrenocortical cellular growth is a critical process in adrenal remodelling, especially during embryonic and postnatal development in humans and primates (Sucheston & Cannon 1968 , Ducsay et al. 1991 . Cell death by apoptosis in the adrenal gland is one of the most common causes of adrenal failure in adrenocortical atrophy (Maisey & Lessof 1969) . Many centrally active neuropeptides and molecules, including neuropeptide Y, ghrelin, adipokines such as TNFa, regulate adrenocortical cell growth by altering intracellular signalling cascades leading to dysregulated growth of adrenocortical cells.
Nesfatin-1 is a recently discovered hypothalamic polypeptide derived from its precursor protein nesfatin/ nucleobindin2 (NUCB2; Oh-I et al. 2006) . Nesfatin-1 is abundantly expressed in various regions of the hypothalamus and the regions of the brain involved in the regulation of food intake (Elmquist et al. 2005) . NUCB2/ nesfatin neurons are activated in response to stress, and central administration of nesfatin-1 elevates circulating adrenocorticotrophin and corticosterone (Stengel & Taché 2011) . Bilateral adrenalectomy resulted in increased NUCB2/nesfatin mRNA levels in the paraventricular nuclei of rats, suggesting the importance of NUCB2/nesfatin in the regulation of the hypothalamic-pituitaryadrenal axis (Könczöl et al. 2010) . NUCB2/nesfatin is also widely expressed in peripheral tissues including the stomach, pancreas as well as in adipose tissue, and regulates various physiological and pathological processes; the main function being suppression of food intake via a leptin independent pathway (Oh-I et al. 2006 , Shimizu et al. 2009 ). Recent studies have associated NUCB2/nesfatin with various forms of cancer. The expression of NUCB2/nesfatin was found to be higher in breast and prostate cancer patients (Suzuki et al. 2012 , Zhang et al. 2013a . A positive correlation was observed between NUCB2/nesfatin, seminal vesicle invasion, lymph node metastasis, angiolymphatic invasion and a higher Gleason score in prostate cancer. More importantly, a poor overall survival rate was observed in patients with prostate cancer patients who had higher NUCB2/ nesfatin levels (Zhang et al. 2013a (Zhang et al. ,b, 2014 . However conflicting observations were found in lung cancer patients, with circulating nesfatin-1 concentrations being lower in lung cancer patients who have undergone weight loss (Cetinkaya et al. 2013) . In another study, nesfatin-1 inhibited the proliferation of a human ovarian epithelial carcinoma cell line (Xu et al. 2013) . We have previously reported nesfatin-1 as a novel adipokine produced from adipocytes and that the circulating and cerebrospinal fluid levels are altered in obese individuals (Ramanjaneya et al. 2010 , Tan et al. 2011 . Adipokines have been implicated in the pathophysiology of metabolic disorders (Lewandowski et al. 2008 , Tan et al. 2009 , Adya et al. 2012 , Randeva et al. 2012 , and have been shown to have direct effects on the adrenal glands (Kargi & Iacobellis 2014) . Given the reports from Ehrhart-Bornstein et al. (2004) demonstrating the existence of intra-adrenal fat, and that the adipokines released regulate adrenal secretion in an autocrine and paracrine manner, we aim to investigate the expression of NUCB2/nesfatin in human adrenal gland and human adrenocortical cells (H295R), as well as the effects of nesfatin-1 on H295R cells. H295R cells are pluripotent adrenocortical cells capable of producing all major zone-specific adrenal steroids (Rainey et al. 1994 ).
Materials and methods

Biochemical reagents
Human nesfatin-1 peptide and nesfatin-1 antibody was obtained from Phoenix Pharmaceuticals, Inc. (Belmont, CA, USA). Insulin-transferrin-selenium (ITS) and Ultroser G were purchased from Pall Life Sciences (Cergy, France). Growth supplement for H295R cells was obtained from Sigma-Aldrich. Accutase required for splitting cells was bought from Cellworks (Buckingham, UK). ECL plus western blotting detection reagents was obtained from GE Healthcare (Little Chalfont, UK). Agarose was obtained from MBI Fermentas, Helena Biosciences (Sunderland, UK). phospo-ERK1/2, phospo-p38, phospo-JNK1/2, ERK1/2, p38 and JNK1/2 antibodies were purchased from Cell Signaling Technology, (Beverly, MA, USA). Polyclonal HRP-conjugated goat anti-rabbit, anti-mouse immunoglobulin/HRP was obtained from Dako (Ely, UK). Precision Plus Protein Standard was obtained from Bio-Rad Laboratories Ltd. A PVDF membrane was obtained from GE Healthcare. All of the primers were obtained from TAGN (Gateshead, UK). Human adrenal glands were obtained under ethical approval, Department of Endocrinology, Metabolism and Internal Medicine, Karol Marcinkowski University of Medical Sciences (Poznan, Poland), bioethics approval number: 556/13. expression studies. DNA fragmentation and apoptosis studies were done following 24 h stimulation with nesfatin-1 in 96-well plates. At the end of the incubation period, cells were washed with ice-cold PBS and subjected to RNA extraction and analysis as described in the following section.
Y1 mouse adrenal tumour cells (a gift from Prof. Henrik Oster, University of Lübeck, Germany) was grown in DMEM supplemented with 15% horse serum, 2.5% fetal bovine serum and 1% penicillin/streptomycin. The cells were incubated in a humidified atmosphere at 5% CO 2 at 37 8C.
Total RNA extraction and cDNA synthesis Total RNA was extracted using the Qiagen RNeasy Mini Kit (Qiagen Ltd), according to the manufacturer's guidelines. The purity of the extracted RNA was measured by a NanoDrop spectrophotometer (Labtech International, Ringmer, UK). A set concentration of RNA was reverse transcribed into cDNA, using M-MuLV Reverse Transcriptase (Fermentas, York, UK) and random hexamers (Promega) as primers.
RT-PCR
NUCB2 gene expression was measured by RT-PCR, using 1 mg total RNA and random hexamer primers as RT primers. A control reaction that omitted reverse transcriptase was included to check for the presence of genomic DNA. The concentration of target mRNA were measured by RT followed by real-time PCR performed on a Applied Biosystems 7500 Fast Real-Time PCR System (Life Technologies Ltd., Paisley, Renfrewshire, UK), according to the manufacturer's instructions. For analysis, quantitative amounts of the gene of interest were standardized against the housekeeping gene GAPDH. Negative controls for all the reactions included preparations lacking cDNA or RNAlacking reverse transcriptase in place of the cDNA. The relative mRNA levels were expressed as a ratio using the 'Delta-delta method' for comparing relative expression results between treatments in real-time PCR (Pfaffl 2001 
Western blotting
Protein lysates were prepared by adding equal amounts of Laemmli buffer to each well, and samples were denatured by sonication and boiling. Samples were separated by SDS-PAGE (10% resolving gel) and transferred to PVDF membranes at 100 V for 1 h in a transfer buffer containing 20 mM Tris, 150 mM glycine and 20% methanol. The PVDF membranes were incubated with primary antibody for nesfatin-1, phospo-ERK1/2, phospo-p38 and phospo-JNK1/2 or total-ERK1/2, p38 and JNK1/2 antibodies at a 1:1000 dilution in Tris-buffered saline (TBS)-0.1% Tween (TBST) and 5% BSA overnight at 4 8C. The membranes were washed, incubated with corresponding secondary anti-rabbit, HRP-conjugated antibody (1:2000) for 1 h at room temperature, and washed for 60 min with TBST. Antibody complexes were visualized using ECL Plus chemiluminescence detection kit. The densities were measured using a scanning densitometer coupled to scanning Software Scion Image (Scion Corporation, Frederick, MD, USA). Standard curves were generated to ensure linearity of signal intensity over the range of protein amounts loaded into gel lanes. Comparisons of densitometric signal intensities were made only within this linearity range.
Immunofluorescent staining and immunohistochemistry
For the animal studies, adult female Wistar rats were used. The animals were maintained under standardized conditions of light (14 h light:10 h darkness cycle, illumination onset at 0600 h) at 23 8C, with free access to standard pellets and tap water. Rats were sacrificed by decapitation; adrenals were immediately removed, and fixed in Bouin's solution. After fixation tissues were dehydrated in 70, 80, 95% alcohol (45 min each), followed by three times incubation in 100% alcohol (1 h each). This was further cleared in xylene (2!, 1 h each). Then tissues where immersed in paraffin (1 h). Embedding of tissues was performed by a paraffin dispenser DP 500 (Bio-Optica, Milano, Italy). Immunofluorescence staining was performed as previously described (Ramanjaneya et al. 2010) . The two-stage immunoperoxidase method with EnVision-HRP complex was used. Adrenals were fixed in Bouin's solution for 24 h, embedded in paraffin and sectioned. 5-6 mm-thick sections were deparaffinised and rehydrated. They were boiled in citrate buffer in three steps procedure (pH 6; 3, 3 and 2.5 min). After each boiling step sections were cooled (3!20 min). Further steps were performed in a humidified chamber at room temperature. In order to inhibit endogenous peroxidase activity slides were incubated in 3% solution of hydrogen peroxide for 10 min. Subsequently, non-specific antibody binding sites were blocked by incubation in goat serum for 30 min. The sections were incubated with the primary antibody overnight at 4 8C polyclonal anti-nesfatin-1 (Phoenix Pharmaceuticals, Inc.) antibody, dilution (1:200). Subsequently, the sections were washed in PBS (5!3 min) and incubated with the secondary (peroxidase-conjugated) antibody for 60 min at 37 8C. Peroxidase activity was detected using the DAB technique (Liquid DAB substrate, chromogen system, Dako, Glostrup, Denmark). Nuclei were counterstained with haematoxylin. Control sections were similarly treated with omission of the primary antibody.
Cortisol and aldosterone measurements
Cells were cultured in six-well plates. Cells were starved overnight in serum-free media for 48 h before experiments. Cells were then washed and incubated in fresh serum-free media with either 100 nM nesfatin-1 or forskolin or angiotensin II for the treatment group and with PBS for the control group at timepoints from 6 to 48 h. At the end of each time point, the supernatant was removed and frozen immediately in liquid nitrogen. Cortisol and aldosterone content of media was determined from three different experiments using commercially available ELISA Kits (ALPCO, Salem, NH, USA), according to the manufacturer's instructions, and normalized to the total protein content. The protein concentrations of cell lysates were determined by the bicinchoninic acid protein quantification assay kit as per manufacturer's protocol (Thermo Scientific, Rockford, MD, USA). The inter-and intra-assay coefficients of variation were !7%.
Cell proliferation assay
H295R and mouse Y1 cells were cultured for 24 h in complete media in 96 wells (1!10 4 cells/well in quadruplet). Prior to treatment, cells were starved overnight in serum free media. Cells were stimulated with indicated concentrations of nesfatin-1 for 24 h at 37 8C/5% CO 2 , the following day. The CellTiter-Glo Luminescent Cell Viability assay (Promega UK Ltd) was utilized, according to the manufacturer's instructions. Following incubation, proliferation was quantified via bioluminescence using a luminometer. Non-seeded wells containing media alone were included as a control.
Apoptosis assay
For fluorescent apoptosis/necrosis studies, cells were treated with nesfatin-1 and subsequently stained with 100 nM YO-PRO-1 Iodide apoptotic stain (Molecular Probes, Invitrogen) for 15 min before being visualized and recorded on an Olympus BX61 fluorescent microscope (Olympus). After three 5 min washes with PBS, the slides were mounted with Vectashield mounting medium containing DAPI counter stain (Vector Laboratories Ltd, Peterborough, UK). The slides were examined under an oil immersion objective (40!) and fluorescent signals were analysed using a Zeiss Axioskop 2 microscope (Carl Zeiss Microscopy Ltd, Cambridge, UK) equipped with a cooled CCD camera (CoolSNAP; Photometrics, Tucson, AZ, USA) controlled by a Power Macintosh computer. For each treatment group, between ten and 15 random fields were selected and examined.
Cellular DNA fragmentation assay
Levels of apoptotic cell death were measured by a quantitative sandwich enzyme immunoassay using a commercial kit i.e. Cellular DNA fragmentation ELISA (Roche Diagnostics Ltd). Cells were labeled with bromodeoxyuridine (BrdU) overnight prior to treatments. Following BrdU incorporation, the cells were washed with PBS and incubated with media containing various treatments for 24 h. At the end of the indicated timepoints, cells were permeabilized to release the cytoplasmic DNA fragments into the supernatant. The supernatants were centrifuged at 300 g for 10 min to bring down the high molecular weight genomic DNA, the low molecular weight BrdU-labeled fragmented DNA released into the supernatants were measured by an ELISA reader (Microplate reader, Molecular Devices, Wokingham, UK) using antibodies against DNA and BrdU.
Calcium measurements
H295R cells were grown to confluence and plated in 96-well black-walled tissue culture plates w24 h prior to experiments. Relative levels of intracellular Ca 2C were measured using the Fluo-4 NW calcium assay kit (Molecular Probes, Invitrogen, Paisley, UK). Cells were loaded with fluo-4 AM in the presence of 2.5 mM probenicid in a commercial phenol-free, magnesium-free Hank's balanced salt solution (HBSS; Invitrogen). The cells were stimulated with various concentrations of nesfatin-1 and fluorescence was measured using a fluorescence plate reader (Tecan GENios, Männedorf, Switzerland; excitation at 485 nm and emission at 520 nm) at room temperature.
Statistical analysis
Data presented in this manuscript are meansGS.E.M. from three or four different experiments. Data were analyzed by either Student's t-test or ANOVA (post hoc analysis: Tukey's test), according to the number of groups compared. All statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software, Inc., San Diego, CA, USA). P!0.05 was considered significant.
Results
Expression of NUCB2 gene and nesfatin-1 protein in human adrenal gland, rat adrenal gland and in human adrenocortical (H295R) cells
The expression of NUCB2 gene and protein in human adrenal gland and human adrenocortical (H295R) cells was analysed by RT-PCR and western blotting. NUCB2 gene and protein are expressed in both human adrenal gland and in H295R cells; human adipose tissue was used as positive control (Fig. 1A and B) . In order to evaluate further the cellular distribution of nesfatin-1 protein in H295R cells, we employed immunohistochemistry using specific antibodies to detect the intracellular distribution of nesfatin-1 in H295R cells. Intense cytoplasmic staining demonstrated the presence of nesfatin-1 protein in the cytoplasm (Fig. 1C) . Within rat adrenal gland section nesfatin-1 immuno-positive substances were present in the cytoplasm of all the zones of adrenal cortex and whilst no reaction was observed in adrenal medulla (Fig. 1D, E, F and G) . No apparent expression was evident in the negative controls, confirming staining specificity.
Effects of nesfatin-1 on cortisol and aldosterone secretion from H295R cells
ELISAs were employed to measure cortisol production and aldosterone secretion from H295R cells following stimulation with nesfatin-1 (100 nM) in a time dependent manner. It was evident from our study that nesfatin-1 did not induce any significant changes in either cortisol or aldosterone production compared to basal levels across the time points measured (6, 24, 36 and 48 h). Forskolin (10 mM) was used as positive control for cortisol secretion, which showed a time dependent increase in cortisol secretion reaching significance at 24 h ( Fig. 2A , **P!0.01). Angiotensin II (100 nM) was used as a positive control for aldosterone secretion, which also showed a time dependent increase in aldosterone secretion reaching significance at 24 h (Fig. 2B , **P!0.01).
Effect of nesfatin-1 stimulation on StAR gene expression in H295R cells
Regulation of StAR mRNA expression and translocation into the mitochondria is the first key rate-limiting step in steroid biosynthesis and StAR deficiency is associated with pathophysiology of lipoid congenital adrenal hyperplasia (Manna & Stocco 2005) . To assess the relative changes in StAR gene expression following nesfatin-1 treatment, H295R cells were treated with nesfatin-1 (100 nM) for 4 and 24 h. Following agonist stimulation the relative changes in StAR mRNA expression were compared by RT-PCR analysis, which showed no significant changes in StAR expression following nesfatin-1 stimulation (Fig. 2C , PO0.05). Stimulation with angiotensin II (100 nM) used as positive control for 24 h induced significant increase in StAR mRNA expression (Fig. 2B , ***P!0.001).
Effect of nesfatin-1 on H295R and Y1 cell viability
Cell proliferation in response to nesfatin-1 (5, 50, 100 nM) stimulation was measured using the CellTiter-Glo Luminescent Cell Viability assay (Promega UK Ltd) at 24 h. Control cells were treated with the same amount of vehicle. Nesfatin-1 significantly inhibited growth of H295R (Fig. 3A , **P!0.01) and Y1 cells (Fig. 3E , *P!0.05) after 24 h compared to vehicle alone. Data points were determined from three independent experiments, each performed in quadruplicate samples and the data points are expressed as percentage decrease over control cells.
Effect of nesfatin-1 on H295R cell apoptosis
Given the previous data, we next assessed if nesfatin-1 promoted apoptosis using a standard DNA fragmentation assay and YO-PRO-1 staining methods. The number of cells stained with YO-PRO-1 (apoptotic green cells) was significantly higher in the nesfatin-1 stimulated group compared to control cells (Fig. 3B) . Therefore, we further evaluated the effects of nesfatin-1 (5, 50 and 100 nM) on H295R cells apoptosis using the DNA fragmentation assay. Nesfatin-1 induced a concentration dependent increase in apoptosis of H295R cells compared to control cells at 24 h (Fig. 3D , **P!0.01). Camptothecin, a known drug to induce apoptosis in various cellular models was used as a positive control for the assay. Camptothecin (2 mM) induced a significant increase in apoptosis (Fig. 3D , ***P!0.001). However, when nesfatin-1 was co-incubated with camptothecin, there was no synergistic or additive effects (Fig. 3D, PO0 .05). Stimulation of Y1 cells with nesfatin-1 induced apoptosis similar to that observed in H295R cells (Fig. 3F , *PO0.05).
Effects of nesfatin-1 on pro-and anti-apoptotic gene expression in H295R cells
Given the preceding data, we assessed the relative changes in pro-and anti-apoptotic genes expression following nesfatin-1 treatment in H295R cells. H295R cells were stimulated with nesfatin-1 (100 nM) for 4 h, and the relative changes in expression of Bax, BCL-XL, BCL-2 and p53 mRNA expression was assessed by RT-PCR analysis. There was a significant increase in Bax ( nesfatin-1 stimulation. However, there were no significant changes in p53 mRNA expression (Fig. 4D, PO0 .05).
Effects of nesfatin-1 on intracellular Ca 2C levels in
H295R cells
Elevation of intracellular calcium through release from intracellular stores such as the endoplasmic reticulum (ER) and a concomitant influx of extracellular Ca 2C into the cell (due to the sustained depletion of Ca 2C from the ER), have been shown to initiate apoptosis (Furuya et al. 1994) .
Therefore, we assessed the effects of nesfatin-1 on intracellular Ca 2C levels in H295R cells. Nesfatin-1 did not have any significant effects on intracellular Ca 2C levels in H295R cells. Angiotensin II (100 nM), used as a positive control, showed an w2.5-fold increase in intracellular Ca 2C levels (Fig. 5) .
Role of MAPK signalling pathways in nesfatin-1 mediated H295R cell proliferation and apoptosis MAPK signalling pathways play a vital role in regulating cell proliferation and apoptosis (Minden et al. 1994 , Xia et al. 1995 , Dhillon et al. 2007 . We employed western blotting to study the effect of nesfatin-1 on key MAPK signalling pathways i.e. ERK 1/2 , p38 and JNK1/2 pathways. H295R cells were stimulated with nesfatin-1 (100 nM) for 2.5, 5, 15, 30 and 60 min. Nesfatin-1 stimulation decreased ERK 1/2 phosphorylation, and increased p38 and JNK1/2 phosphorylation in H295R cells (Fig. 6 ). The immediate, significant effects of nesfatin-1 induced activation of p38 and JNK1/2 and down regulation of ERK1/2 suggest a likely direct physiological role for these MAPK elements.
Discussion
This is the first study demonstrating the expression of NUCB2/nesfatin gene and nesfatin-1 protein in human adrenal gland and human adrenocortical cells (H295R). The distribution of nesfatin-1 in rat adrenal sections appears to be more in adrenal cortex compared to adrenal medulla as observed by immunohistochemistry. Due to abundance of lipid droplets content in zona glomerulosa (ZG) and zona fasciculata (ZF), immunopositive signal seems to be weaker and more diffused in these zones in comparison to zona reticularis (ZR), where the entire cytoplasm is stained. Our results also show strong immunopositive signal in endothelial cells of the capillary bed, especially in ZG and ZF. We also present novel data of nesfatin-1's effects on steroid production, cell viability and apoptosis in human adrenocortical cells (H295R). Stimulation of H295R cells with nesfatin-1 had no significant effects on glucocorticoid (cortisol) and mineralocorticoid secretions as well as StAR gene expression; the StAR gene encodes for the transport protein that regulates cholesterol transfer within the mitochondria, which is the rate limiting step in the production of steroid hormones. However, nesfatin-1 decreased cell proliferation and induced apoptosis in H295R cells. This is in agreement with a recent study, which showed that nesfatin-1 inhibits ovarian epithelial carcinoma cell Effects of nesfatin-1 on (A) cortisol and (B) aldosterone secretion from H295R cells. H295R cells (four replicates) were stimulated with nesfatin-1 (100 nM), forskolin (10 mM) or angiotensin II (Ang II) (100 nM) at 6, 24, 36 and 48 h. At various timepoints media was collected for cortisol and aldosterone assay, and protein lysates from each treatment group were collected for normalization of steroid estimation. (C) Effects of nesfatin-1 on STAR protein (StAR) mRNA levels in H295R cells. Cells were cultured for the indicated periods in the presence or absence of nesfatin-1 (100 nM). StAR mRNA expression levels were normalized against GAPDH mRNA expression. Data are expressed as meanGS.E.M., from four independent experiments. *P!0.05 and **P!0.01.
proliferation (Xu et al. 2013) . These effects may be tissue and cell type specific as other researchers have found conflicting results in breast cancer cell models (MCF-7 and SK-BR-3), i.e. NUCB2/nesfatin significantly increased cell proliferation as well as migration and invasion properties in MCF-7 and SK-BR-3 cells (Suzuki et al. 2012) . Apoptosis is a critical component of adrenal cortical development and remodelling. The adrenal cortex undergoes apoptosis of different zones during fetal and adult life. During postnatal adrenal cortical remodelling, the inner portion of the cortex mainly undergoes apoptosis (Wyllie et al. 1973a,b) . However, in the adult human adrenal cortex, cellular apoptosis appears to be highest in the external ZG and decreased in the internal ZF and ZR.
Although the reason for this reversal of the apoptotic pattern is unknown, it does suggest that the role of apoptosis in adrenal cortical growth and remodelling may play a key role in tissue remodelling during fetal and adult life. Our findings of nesfatin-1 inducing apoptotic effects on adrenocortical cells may shed some light on the possible role of NUCB2/nesfatin in adrenal remodelling.
Apoptosis is a tightly regulated physiological process in which cell death is executed for the maintenance of a steady state homeostasis under normal physiological conditions, and for responding to various stimuli. Various regulatory proteins control these processes, and genetic aberrations in the control of the transcription of these proteins are present in all cancers (Le Beau et al. 1985, 
Figure 4
Effects of nesfatin-1 (100 nM) stimulation for 4 h on pro and anti-apoptotic genes expression in H295R cells; mRNA expression levels were normalized against GAPDH mRNA expression. Data are expressed as meanGS.E.M., from four independent experiments. *P!0.05 and **P!0.01.
Adams & Cory 1998). The members of BCL-2 proteins are potent regulators of the apoptotic process (Adams & Cory 1998 , Borner 2003 , Donovan & Cotter 2004 , Sharpe et al. 2004 . They consist of both pro-and anti-apoptotic genes that induce opposing effects on mitochondria, including the anti-apoptotic protein Bcl-2 and the pro-apoptotic proteins Bax: BCL-2 family members have the ability to heterodimerize and modify each other's function. Earlier studies have demonstrated an increase in p53 expression and Bax-BCL-2 ratio favouring p53 dependent Bax induced apoptosis (McDonnell et al. 1992 , Antonsson & Martinou 2000 . In addition, p53 has a transcriptionindependent role in apoptosis induction by promoting both activation and insertion of Bax into the mitochondrial membrane (Miyashita & Reed 1995) . Thus, we investigated whether nesfatin-1 induced apoptosis in H295R cells could be by modulation of the expression of Bax, BCL-XL, BCL-2 and p53 genes. Our results suggest that nesfatin-1 induced apoptosis in H295R cells involves the Bax, BCL-XL and BCL-2 genes. The relevance of these findings on adrenal physiology remains to be explored further. Alterations in intracellular calcium homeostasis due to increased calcium influx or inhibition of calcium efflux is one of the early crucial events involved in apoptosis (Orrenius et al. 1992) . Therefore, we studied the effects of nesfatin-1 on intracellular calcium levels in H295R cells. We found no significant changes in intracellular calcium levels suggesting that nesfatin-1 induced apoptosis in H295R cells maybe calcium independent. Further experiments are needed to clarify this point. Notably, calcium independent apoptosis has previously been observed in prostate cancer and in cervical cancer cells (Wang et al. 2004 , Savino et al. 2006 . MAPK are crucial for transmission of signal from cell surface receptors to the transcriptional machinery located in the nucleus (Cobb & Goldsmith 1995 , Hill & Treisman 1995 . MAPK signalling pathways are pivotal in the regulation of cell growth, survival, cell cycle regulation, differentiation and gene expression (Johnson & Vaillancourt 1994) . We report for the first time that nesfatin-1 stimulation decreased ERK 1/2 phosphorylation, and increased p38 and JNK1/2 phosphorylation in H295R cells.
These findings are in agreement with previous reports from various cellular models that have reported the 
Figure 6
Effects of nesfatin-1 (100 nM) stimulation on ERK1/2, p38 and JNK1/2 protein phosphorylation and corresponding total protein expressions in H295R cells at 2.5, 5, 15, 30 and 60 min. Western blot analysis of protein extracts from H295R cells demonstrate that the antibody against p-ERK1/2, total ERK1/2, p-p38, total p38, p-JNK1/2 and total JNK1/2 recognized bands with apparent molecular weights of 42, 44, 43, 43, 46 and 54 kDa, respectively. Data are expressed as meanGS.E.M., from three independent experiments. **P!0.01 and ***P!0.001. A full colour version of this figure is available at http://dx.doi.org/10.1530/JOE-14-0496.
activation of p38 and JNK1/2 to be associated with programmed cell death and/or necrosis pathways, and the activation of ERK 1/2 with cell survival pathways (Minden et al. 1994 , Xia et al. 1995 , Dhillon et al. 2007 . Future studies should involve inhibiting p38 and JNK1/2 pathways. It would also be interesting to evaluate the effects of NUCB2/nesfatin in other cancer cell models.
In conclusion, we found that NUCB2/nesfatin is expressed in human adrenal gland and human adrenocortical cells. Stimulation with nesfatin-1 inhibits adrenocortical cell growth and promotes apoptosis, potentially via the involvement of Bax, BCL-XL and BCL-2 genes as well as ERK 1/2 , p38 and JNK1/2 signalling cascades. This has implications for understanding the role of NUCB2/nesfatin in adrenal zonal development. NUCB2/nesfatin may also be a therapeutic target for adrenal cancer. However, further studies using in vivo models are needed to clarify these concepts.
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